Core Points - The State Council's executive meeting approved the draft regulation for the management of clinical research and application of new biomedical technologies, aiming to promote innovation and accelerate the transformation of research outcomes in the biomedical industry [1] - The regulation emphasizes the dual focus on development and safety, ensuring the quality and safety of clinical applications while effectively preventing various risks [1] - The establishment of this regulation is seen as a significant step towards modernizing the governance system and capabilities in the biomedical field, facilitating the integration of research and application, and clarifying responsibilities among research institutions, enterprises, and medical organizations [1] Industry Summary - The biomedical technology sector is recognized as one of the fastest-growing and most challenging areas within the life sciences, providing new means for disease diagnosis and treatment while also posing risks related to privacy, biosecurity, public safety, and social ethics [1] - The regulation aims to enhance the quality and safety of medical practices, safeguard human dignity and health, and promote medical advancements through standardized clinical research and application processes [1] - By addressing the barriers between research and application, the regulation is expected to expedite the availability of cutting-edge biomedical technologies to the public, while also reinforcing risk warning and emergency management mechanisms [1]

Core Viewpoint - Biomerica, Inc. has appointed Eric B. Chin to its Board of Directors, enhancing its corporate governance and financial oversight as it scales commercialization efforts for its diagnostic and therapeutic products [1][7]. Group 1: Appointment Details - Eric B. Chin has been appointed as Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee and the Compensation Committee, effective June 4, 2025 [1]. - Chin replaces Cathy Coste, whose resignation was not due to any disagreement with the company [3]. Group 2: Eric B. Chin's Background - Chin is an accomplished financial executive with over 20 years of experience in public and private healthcare organizations [2][7]. - He currently serves as CFO of Akido Labs, where he successfully raised $60 million in recent financing [2][7]. - His previous roles include executive positions at Astrana Health, Public Storage, and Alexandria Real Estate Equities, and he began his career at Ernst & Young LLP [2]. Group 3: Company Overview - Biomerica, Inc. develops, patents, manufactures, and markets advanced diagnostic and therapeutic products aimed at enhancing health and reducing healthcare costs, primarily focusing on gastrointestinal and inflammatory diseases [4]. - The company's inFoods IBS test assesses patients' immunoreactivity to specific foods, providing targeted dietary recommendations to alleviate IBS symptoms [5].

Core Insights - Allegro NV has reported positive results from preclinical studies of hydrocelin (ALG-001), an injectable microparticle hydrogel, showing no signs of toxicity over 4 and 13 weeks [1][4][8] - The company plans to initiate a pivotal clinical study in osteoarthritis patients in Belgium later this year [1][2][8] - Hydrocelin is designed to restore the shock-absorbing capacity of synovial fluid in joints, potentially providing pain relief and protecting cartilage [3][5] Company Overview - Allegro NV is a private biomedical company focused on developing treatments for degenerative joint diseases using its proprietary nanotechnology platform, INTRICATE [6] - Hydrocelin is positioned as a potential first-in-class, disease-modifying treatment for osteoarthritis, with clinical studies in humans expected to commence later this year and a commercial launch targeted for 2027 [6] Product Details - Hydrocelin consists of cross-linked microparticles that act as shock absorbers in the synovial fluid, enhancing impact absorption and optimizing load distribution [5] - The treatment is minimally invasive and aims to promote joint homeostasis while providing pain relief and protecting cartilage [5]

Registration No. 333-268283 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A As filed with the U.S. Securities and Exchange Commission on January 9, 2023 (AMENDMENT NO. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PONO CAPITAL THREE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Cayman Islands 6770 N/A (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identific ...